We are live on ! Find out more
VTGN icon

VistaGen Therapeutics
VTGN

47 hedge funds and large institutions have $45.3M invested in VistaGen Therapeutics in 2024 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 10 increasing their positions, 13 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 3

9% more funds holding

Funds holding: 43 → 47 (+4)

4.05% less ownership

Funds ownership: 60.44% → 56.4% (-4%)

20% less capital invested

Capital invested by funds: $56.3M → $45.3M (-$11M)

23% less repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 13

77% less call options, than puts

Call options by funds: $370K | Put options by funds: $1.64M

Holders
47
Holders Change
+4
Holders Change %
+9.3%
% of All Funds
0.67%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
10
Reduced
13
Closed
3
Calls
$370K
Puts
$1.64M
Net Calls
-$1.27M
Net Calls Change
-$2.76M

Top Buyers

Rank Fund Capital Flow
1
ACM
ADAR1 Capital Management
Texas
+$556K
2
Renaissance Technologies
Renaissance Technologies
New York
+$429K
3
VU
Valence8 US
Massachusetts
+$117K
4
Millennium Management
Millennium Management
New York
+$86.5K
5
HighTower Advisors
HighTower Advisors
Illinois
+$71.1K

Top Sellers

Rank Fund Capital Flow
1
GPP
Great Point Partners
Connecticut
-$2.92M
2
Citadel Advisors
Citadel Advisors
Florida
-$1.05M
3
AC
Armistice Capital
New York
-$1.04M
4
Geode Capital Management
Geode Capital Management
Massachusetts
-$108K
5
Barclays
Barclays
United Kingdom
-$67K
Name Holding Trade Value Shares
Change 		Change in
Stake
TCM
1
TCG Crossover Management
California
$8.06M – – –
BI
2
BVF Inc
California
$6.02M – – –
Vanguard Group
3
Vanguard Group
Pennsylvania
$5.4M – – –
SC
4
Stempoint Capital
New York
$4.9M -$6.11K -1,790 -0.1%
CC
5
Commodore Capital
New York
$4.74M – – –
NCM
6
Nantahala Capital Management
Connecticut
$4.57M – – –
SFM
7
Sphera Funds Management
Israel
$2.43M – – –
GPP
8
Great Point Partners
Connecticut
$2.03M -$2.92M -855,263 -56%
BlackRock
9
BlackRock
New York
$1.24M +$32K +9,382 +2%
Citadel Advisors
10
Citadel Advisors
Florida
$969K -$1.05M -307,760 -49%
Geode Capital Management
11
Geode Capital Management
Massachusetts
$778K -$108K -31,570 -11%
Renaissance Technologies
12
Renaissance Technologies
New York
$574K +$429K +125,700 +194%
Goldman Sachs
13
Goldman Sachs
New York
$531K +$4.36K +1,279 +0.7%
ACM
14
ADAR1 Capital Management
Texas
$491K +$556K +163,078 New
BCM
15
BML Capital Management
Indiana
$452K – – –
State Street
16
State Street
Massachusetts
$267K – – –
William Blair & Company
17
William Blair & Company
Illinois
$266K – – –
AI
18
AdvisorShares Investments
Maryland
$204K +$54.6K +16,000 +31%
Two Sigma Investments
19
Two Sigma Investments
New York
$185K -$20.4K -5,969 -9%
Susquehanna International Group
20
Susquehanna International Group
Pennsylvania
$157K -$44.4K -13,013 -20%
Northern Trust
21
Northern Trust
Illinois
$149K -$1.81K -531 -1%
VU
22
Valence8 US
Massachusetts
$103K +$117K +34,376 New
American Century Companies
23
American Century Companies
Missouri
$90.9K -$403 -118 -0.4%
Squarepoint
24
Squarepoint
New York
$83K +$55.2K +16,180 +142%
Millennium Management
25
Millennium Management
New York
$76.3K +$86.5K +25,337 New
1
2

VTGN Hedge Fund Activity: Q3 2024 in Review

47 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in VistaGen Therapeutics (VTGN) for Q3 2024, worth a combined $45.3M — down 20% from $56.3M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new VTGN positions and 3 closed out — a net gain of 4 holders — while 10 added to existing stakes and 13 trimmed.

The largest buyer was ADAR1 Capital Management, opening a new position worth an estimated $556K. The largest seller was Great Point Partners, cutting an estimated $2.92M.

  • 47 institutional investors held VistaGen Therapeutics (VTGN) as of Q3 2024, up from 43 in Q2 2024.
  • Funds reported $45.3M of VistaGen Therapeutics stock for Q3 2024, down 20% quarter-over-quarter.
  • 7 funds opened new VistaGen Therapeutics positions in Q3 2024 and 3 closed out, a net change of +4 holders.
  • The largest VistaGen Therapeutics buyer in Q3 2024 was ADAR1 Capital Management, an estimated $556K added.
  • The largest VistaGen Therapeutics seller in Q3 2024 was Great Point Partners, an estimated $2.92M sold.

Based on aggregated 13F filings for Q3 2024.